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Abstract
Background: An analysis of NIH funding in 1996 found that the strongest predictor of funding, disability-adjusted life-years
(DALYs), explained only 39% of the variance in funding. In 1998, Congress requested that the Institute of Medicine (IOM)
evaluate priority-setting criteria for NIH funding; the IOM recommended greater consideration of disease burden. We
examined whether the association between current burden and funding has changed since that time.
Methods: We analyzed public data on 2006 NIH funding for 29 common conditions. Measures of US disease burden in 2004
were obtained from the World Health Organization’s Global Burden of Disease study and national databases. We assessed
the relationship between disease burden and NIH funding dollars in univariate and multivariable log-linear models that
evaluated all measures of disease burden. Sensitivity analyses examined associations with future US burden, current and
future measures of world disease burden, and a newly standardized NIH accounting method.
Results: In univariate and multivariable analyses, disease-specific NIH funding levels increased with burden of disease
measured in DALYs (p = 0.001), which accounted for 33% of funding level variation. No other factor predicted funding in
multivariable models. Conditions receiving the most funding greater than expected based on disease burden were AIDS
($2474 M), diabetes mellitus ($390 M), and perinatal conditions ($297 M). Depression ($719 M), injuries ($691 M), and
chronic obstructive pulmonary disease ($613 M) were the most underfunded. Results were similar using estimates of future
US burden, current and future world disease burden, and alternate NIH accounting methods.
Conclusions: Current levels of NIH disease-specific research funding correlate modestly with US disease burden, and
correlation has not improved in the last decade.
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Introduction
The National Institutes of Health (NIH) is the largest public
funder of biomedical research worldwide [1,2], with a budget that
has grown from $11.9 billion in 1996 to $28.5 billion in 2006 [3].
In the mid-1990s, Congress and the public raised concerns that
disease-specific funding allocations by the NIH failed to adequate-
ly reflect burden of disease and incorporate public input [4]. In
response, Congress requested that the Institute of Medicine (IOM)
assess the NIH funding apportionment processes. In its 1998
report, Scientific Opportunities and Public Needs: Improving Priority Setting
and Public Input at the National Institutes of Health, the IOM
recommended improved tracking of disease-specific funding and
development of a new priority-setting process [4].
A landmark study comparing disease burden to NIH funding
levels was published in 1999 [5]. For 29 common conditions,
the study examined a variety of measures of societal burden,
recognizing that none by itself completely captures relative impacts
of diseases. Disease incidence and prevalence were unrelated
to funding, while mortality and years of life lost (YLLs) weakly
correlated with funding. Disability-adjusted life years (DALYs)—a
measure that estimates the equivalent number of healthy years lost
due to disability or early death [6,7]—were more strongly
predictive. Using DALYs as the best single predictor, only 39%
of the variance in NIH funding could be explained. The prior
analysis was limited to evaluation of univariate predictors, and did
not attempt to evaluate whether funding aligned with other
measures of disease burden. The NIH Reform Act of 2006 re-
emphasized the NIH’s role in identifying research to meet public
health challenges, and mandated submission of a biennial report to
Congress regarding disease-specific funding amounts [8]. There
has been no recent comprehensive study of US disease burden and
NIH funding, and an analysis of only one of its institutes has been
performed [9].
To determine whether the NIH has developed processes that
better align funding with burden, we assessed the correlation
between NIH funding and burden of disease, and compared
results with those reported 10 years ago [5]. We also considered
other potential predictors of funding and assessed the association
of NIH funding with estimates of future and global disease burden.
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Methods
In a cross-sectional study, we compared measures of US and
world disease burden and sociopolitical factors from 2004 to NIH
funding levels in 2006. The study design was modeled on methods
previously established [5], which used 1994 burden data and 1996
NIH funding to reflect an expected lag in availability of data on
disease burden. Each disease was defined using pre-specified sets of
International Classification of Diseases, 9th revision, Clinical Modification
(ICD-9) codes, which were applied to public sources of information
on disease burden [10].
Data Sources
Amounts of NIH funding for disease categories were obtained
directly from the NIH for the year 2006 (Table 1). These estimates
were annually consolidated from figures supplied by indivi-
dual NIH Institutes and Centers (http://www.nih.gov/news/
fundingresearchareas.htm) [11]. In 2006 and prior years, NIH
Institutes and Centers categorized spending in a variety of
manners to satisfy diverse reporting requirements, and calculated
condition-specific total funds in a non-mutually exclusive manner.
Thus, funding for a particular trial or biomarker could have been
attributed to multiple conditions.
Data denoting disease burden were collected frommultiple sources
(Table 1). First, world and North American disease-specific data were
obtained from the Global Burden of Disease (GBD) Project the
World Health Organization (WHO) [12,13,14]. We used GBD’s
North American data for US estimates. The GBD systematically
collects timely disease-specific epidemiologic information and models
missing data to estimate a variety of measures of burden [15,16]. We
used 2004 GBD estimates because they were likely to be the most
recent publicly available data at the time decisions were made for the
2006 funding cycle. No other centralized, systematic source of broad
national disease-specific burden estimates was identified.
We evaluated five disease burden categories from the GBD:
incidence, prevalence, mortality, YLLs, and DALYs [14]. YLLs
Table 1. NIH Research Funds and Measures of Disease Burden for 29 Conditions.
Condition or Disease NIH Research Funds
Measure of Disease Burden in North America*
thousands (rank)
millions of dollars
(% of total) Incidence Prevalence Mortality
Years of
Life Lost
Disability-Adjusted
Life-Years
AIDS 2902 (24.3) 142 (19) 1275 (15) 14 (16) 279 (13) 583 (14)
Diabetes mellitus 1038 (8.7) 1200 (9) 21663 (2) 84 (7) 563 (7) 1473 (6)
Perinatal conditions 789 (6.6) 45 (21) 3516 (7) 17 (14) 578 (6) 793 (10)
Breast cancer 718 (6.0) 222 (13) 1875 (11) 53 (10) 488 (8) 684 (12)
Dementia 643 (5.4) 714 (10) 3108 (8) 132 (5) 306 (11) 1359 (8)
Alcohol abuse 511 (4.3) 2641 (6) 9553 (4) 8 (17) 121 (16) 1837 (4)
Dental and oral disorders 413 (3.5) 109774 (1) 41152 (1) 0 2 (27) 267 (18)
Cirrhosis 408 (3.4) 43 (22) 303 (21) 30 (12) 360 (10) 455 (16)
Ischemic heart disease 398 (3.3) 1336 (7) 2347 (10) 531 (1) 2695 (2) 3048 (3)
Schizophrenia 364 (3.1) 42 (23) 1561 (13) 1 (24) 5 (25) 522 (15)
Injuries 355 (3.0) 3747 (5) 241 (23) 182 (2) 3448 (1) 4484 (2)
Pneumonia 351 (3.0) 4178 (4) 75 (27) 68 (9) 294 (12) 315 (17)
Prostate cancer 348 (2.9) 149 (18) 1032 (16) 38 (11) 152 (14) 253 (20)
Stroke 342 (2.9) 373 (12) 2733 (9) 176 (4) 791 (4) 1336 (9)
Depression 335 (2.8) 16417 (3) 8207 (5) 1 (24) 3 (26) 4564 (1)
Asthma 283 (2.4) 1278 (8) 19100 (3) 4 (20) 53 (19) 755 (11)
Colorectal cancer 269 (2.3) 150 (17) 713 (18) 70 (8) 466 (9) 609 (13)
Lung cancer 266 (2.2) 196 (15) 706 (20) 181 (3) 1331 (3) 1384 (7)
Sexually transmitted diseases 264 (2.2) Not available Not available 0 2 (27) 65 (26)
Parkinson’s disease 208 (1.7) 90 (20) 1025 (17) 21 (13) 66 (18) 263 (19)
Tuberculosis 150 (1.3) 11 (27) 11 (28) 1 (24) 7 (24) 10 (29)
Multiple sclerosis 110 (0.9) 9 (28) 176 (25) 4 (20) 45 (20) 118 (24)
Epilepsy 103 (0.9) 207 (14) 1677 (12) 2 (23) 31 (22) 160 (22)
Ovarian cancer 102 (0.9) 24 (26) 143 (26) 17 (14) 140 (15) 161 (21)
Cervical cancer 97 (0.8) 29 (24) 225 (24) 7 (18) 86 (17) 125 (23)
Chronic obstructive pulmonary disorder 67 (0.6) 429 (11) 6923 (6) 132 (5) 644 (5) 1647 (5)
Uterine cancer 28 (0.2) 25 (25) 301 (22) 7 (18) 45 (20) 84 (25)
Peptic ulcer disease 17 (0.1) 192 (16) 712 (19) 4 (20) 24 (23) 40 (27)
Otitis media 17 (0.1) 17679 (2) 1360 (14) 0 1 (29) 35 (28)
Funding rates by disease were obtained from the NIH for 2006. Estimates of incidence, prevalence, mortality, disability-adjusted life-years lost, and years-of-life-lost are
total annual counts, in 1000s, for North America, obtained from the 2004 update of the World Health Organization’s Global Burden of Disease project.
doi:10.1371/journal.pone.0016837.t001
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for each disease were calculated by totaling the differences
between life expectancy and age at death. DALYs were estimated
based on YLL and on standardized weighting schemes for
disability applied to those surviving with disease [6,7]. GBD
estimates for the US were based on analyses of comprehensive
death certificate data, national incidence estimates, and a
systematic review of published epidemiological studies.
To evaluate other estimates of disease burden, we used 2004 US
inpatient and outpatient healthcare databases categorized by
diagnosis, each of which includes large samples with weights to
generate nationally representative estimates (Supporting Table
S1). The number of hospital discharges, total length of stay, and
mean hospital charges for disease-specific principal diagnoses were
derived from the National Inpatient Sample (NIS) [17]. The
number of visits to emergency departments and outpatient hospital
clinics were derived from the National Hospital Ambulatory Care
Survey (NHAMCS) and the National Ambulatory Care Survey
(NAMCS) [18]. In both NIS and NHAMCS, community hospitals
were defined as non-federal, short-stay hospitals [19,20].
Public interest could also influence funding levels through
lobbying efforts, additional funding support from private founda-
tions, or by directly stimulating the interest of investigators, and
this could influence funding levels. To begin to assess the influence
of public interest, we determined the number of disease-specific
newspaper articles published in the top 10 US newspapers with
highest distribution, as well as broadcast television news reports
from national networks, using disease-specific keyword searches of
LexisNexis News [21] and Vanderbilt Television News Archive
[22]. To estimate the influence of specific interest group advocacy,
the total US disease-specific charity revenue was similarly
calculated for public charities receiving more than $500,000 in
public support [23].
Scientific productivity in a given area could stimulate further
interest from researchers and the NIH, and could result in targeted
funding. As surrogate measures of scientific productivity, we tallied
the number of disease-specific patents submitted [24] and articles
published and listed in PubMed [25] in the 10 medical journals
with the highest impact factor scores using key word searches [26].
Analysis
The relationship between 2006 NIH funding levels and 2004
US disease burden metrics was designated the a priori primary
analysis. All predictor and outcome variables were log-transformed
to reduce positive skew.
Univariate linear regression was first performed to replicate the
prior study design [5]. This approach was preferred to correlation
to allow for adjustment and to acknowledge that funding level was
the dependent variable to be predicted. Expected funding levels in
2006 were calculated with correction for the log-transformation by
applying measures of disease burden to fitted models predicting
funding [27,28]. To account for inflation, the actual and expected
funding levels for 1996 were inflated to 2006 dollars [29].
Standard, forward stepwise multivariable linear regression analysis
included all variables of disease burden, including those with
p,0.05 in the final model. We did not evaluate interactions. F-
statistics were used to estimate differences in explanatory power
(significant if p,0.05). A separate forward stepwise multivariable
model was constrained so that diseases with no burden would
receive zero funding, mimicking a theoretical funding process that
determines allocations proportional to the disease burden. For this
model, we defined the dependent variable as the ratio of dollars to
DALYs for each of the included conditions. Separate multivariable
models included measures of public interest and scientific
productivity. In additional sensitivity analyses, we evaluated the
association of funding levels with worldwide disease burden in
2004, and with projections for 2015 and 2030 for both the US and
worldwide [30]. A final analysis evaluated whether a new NIH
accounting method for disease-specific funding introduced in 2007
produced different results. Explanatory power of the models was
estimated with adjusted R2 values; an adjusted R2 value was also
determined for the analysis of 1996 funding levels using data
derived from this prior publication. The Stata statistical package
(Version 10, College Station, Texas) was used for all analyses.
Results
In 2006, the total NIH budget was $28.5 billion, with $11.9
billion devoted to the 29 included conditions. Disease funding
ranged from $17 million (M) for peptic ulcer disease and otitis
media, to $2902 M for AIDS, with a median of $335 M
(6standard deviation $537 M; Table 1). Other metrics from the
GBD (Table 1); US inpatient, emergency room, and outpatient
(Supporting Table S1); and public interest and scientific
opportunity (Supporting Table S2) varied by disease.
In the univariate analysis, NIH funding was most strongly
associated with burden of disease measured in DALYs (p = 0.001;
Table 2). YLLs (p = 0.03), inpatient hospital discharges (p = 0.05),
and total hospital days (p = 0.02) were also associated with funding
levels.
In standard multivariable analysis, DALYs was the only
significant predictor of NIH funding level retained in the final
model, so the analysis became univariate. In 2006, the degree of
correlation between NIH funding and disease burden as measured
by DALYs alone was less than in 1996: Only 33% of NIH funding
variance was explained in 2006 compared to 39% in 1996.
Differences between actual and expected funding based on burden
of disease in DALYs were estimated for 2006 and compared to 1996
funding levels (Table 3; Figure 1). Depression received the least
funding compared to expected, and AIDS the most, consistent with
findings from 1996. Relative to expected funding, AIDS, diabetes,
and perinatal conditions were the three diseases with the largest
amounts of funding, while depression, injuries, and COPD received
the least funding (Table 3). The largest positive 10-year gains in
actual NIH funding relative to expected were AIDS (+$809 M),
perinatal conditions (+$420 M), and diabetes (+$193 M); by
contrast, injuries (2$578 M), depression (2$541 M), chronic
obstructive pulmonary disease (2$512 M), and ischemic heart
disease (2$459 M) decreased most sharply (Figure 1).
In standard multivariable regression models including measures
of public interest and scientific productivity, the total charity
revenue for a given disease in 2006 (p= 0.04) was also predictive of
funding in addition to DALYs (p = 0.006). A model including both
variables explained 41% of the variation in NIH funding levels.
In multivariable models constrained to require that diseases
resulting in no burden of illness receive no NIH funding
(equivalent to requiring an intercept of zero-zero in the regression
line, expressed in the dashed line of Figure 2), expected funding
amounts were generally similar to those found with the
unconstrained multivariable model (Table 3; Figure 3).
To determine if NIH funding might better correlate with world
or future disease burden, we performed sensitivity analyses with
global measures and future projections (2015 and 2030), all
derived from the GBD project (Supporting Table S3). When
restricted to global measures, mortality (p = 0.05) and DALYs
(p = 0.001) were predictive of funding in univariate analyses
(adjusted R2 values 0.11 and 0.30), but only DALYs were retained
in all the multivariable models of both global measures and future
predictions. Correlation of funding with disease burden was not
NIH Funding Levels and Burden of Disease
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improved when data utilizing new NIH accounting methods was
used (adjusted R2= 0.27) compared to prior methods (adjusted
R2= 0.34) applied to 2007 data, the first year for which the new
methods were available.
Discussion
In the 10 years since an initial assessment of the correlation of
NIH funding with disease burden [5] and an IOM report
recommending new NIH funding priority-setting criteria [4], NIH
funding is no better aligned with US disease burden. Furthermore,
diseases that were previously funded more than expected–such as
AIDS, breast cancer, and diabetes–continue to receive funding
greater than predicted by burden of disease, while most conditions
that were previously underfunded remain underfunded. Adding
measures of disease burden to the model and constraining it to
assure that diseases with no burden would receive no funding
minimally affected the overall relationship between burden
and funding. Neither global nor future disease burden were
more closely related to NIH funding, and newly implemented
NIH disease-specific accounting practices did not improve the
correlation.
Although the IOM report on NIH funding recommended
ongoing assessment of alignment of NIH funding with disease
burden, it also recognized other important criteria for setting
funding priorities [4]. These criteria included research quality,
scientific innovation and opportunity, portfolio diversification, and
infrastructure building. Other experts have proposed a similar
framework to guide funding decisions [31]. Additional factors to
consider may include transmissibility or population risk, collateral
benefits to disease control, and public interest. Given these other
potential contributors to decision-making about disease funding,
perfect alignment with DALYs or any other measure of disease
burden would not be expected.
It is unclear why particular conditions remain under- or
overfunded relative to disease burden. The difficulty of attributing
basic science research—a large portion of the NIH portfolio—to
individual diseases complicates implementation of any disease-
based allocation process [32]; however, some discrepancies are
particularly dramatic. Spending for AIDS research, the disease
with greatest funding compared to expected, may be justified due
to the potential threat associated with its spread, to past successes
in treating and even eliminating other infectious diseases, and to a
greater burden in lower income countries. However, AIDS
funding remained greater than predicted even when worldwide
and projected burden were considered, and strong political
influences may be important in maintaining high levels of funding
in the US. Also, congressionally-mandated research support for
rare illnesses may explain greater funding for some diseases with
little burden [33,34,35]. Conditions typically associated with
substance use or mental health diagnoses tended to be under-
funded (e.g., lung cancer, chronic obstructive pulmonary disease,
alcoholism, and depression). Charity revenue, used as a proxy for
disease-specific interest-group advocacy, was associated with
funding levels and may have contributed through lobbying efforts
or by providing collateral support for research and training to
encourage NIH submissions in specific disease areas. The
availability of proven cost-effective interventions (e.g., tobacco-
related prevention strategies) [36] may also influence funding since
development of new interventions may be unnecessary when
effective strategies have already been identified [37].
Over the 10-year interval, funding for several conditions notably
increased compared to expected. For example, the National
Institute of Allergy and Infectious Diseases initiated a concerted
response to bioterrorism following the terrorist attacks on Sept. 11,
2001, anthrax incidents, and severe acute respiratory syndrome
(SARS) outbreak in 2002, and this may have augmented support
for pneumonia-related research [38]. Conversely, the relative
funding increase for perinatal conditions appears primarily due to
a 55% reduction in associated DALYs over the last decade since
funding increases over the same period paralleled overall growth
in the NIH budget [39]. Finally, an increase in relative funding for
diabetes research may have been precipitated by Congressional
actions in 1997 requiring development of a comprehensive
Table 2. Univariate Predictors of NIH Disease-Specific Funding in Fiscal Year 2006.
Predictor Predicted change in funding associated with a 2-fold increase in the predictor*
Relative Increase 95% CI P-Value Adjusted R-squared Value
Disease Burden Measure
Incidence 1.05 (0.91–1.20) 0.51 20.02
Prevalence 1.15 (0.97–1.36) 0.10 0.06
Mortality 1.12 (0.98–1.27) 0.08 0.08
Disability-adjusted life-years 1.37 (1.16–1.63) 0.001 0.33
Years-of-life-lost 1.15 (1.01–1.31) 0.03 0.12
Number of hospital discharges 1.21 (1.00–1.46) 0.05 0.11
Total hospital days 1.24 (1.03–1.48) 0.02 0.15
Average hospital charges 1.49 (0.76–2.93) 0.23 0.02
Outpatient physician visits 1.11 (0.90–1.37) 0.30 0.004
Outpatient hospital and emergency room visits 1.10 (0.92–1.31) 0.27 0.01
Public Interest Measure
Newspaper articles 1.13 (1.02–1.25) 0.02 0.14
Television news broadcasts 1.19 (1.04–1.36) 0.02 0.17
Charity revenue 1.07 (1.02–1.11) 0.004 0.24
*Predictors and outcome are log-transformed to reduce positive skew.
doi:10.1371/journal.pone.0016837.t002
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diabetes research plan and allocating $150 million to a new
funding program for Type I Diabetes Research [40].
Lack of improvement in alignment between funding and disease
burden may not indicate neglect of the 1998 IOM recommenda-
tions by the NIH; there are several other possible explanations.
First, basic science research has consistently accounted for 55% of
NIH spending and it is difficult to credit specific disease for much
of this research, contributing uncertainty to the analysis and
reducing correlations between funding levels and disease burden.
Second, NIH funds committed at the time of the 1998 IOM
publication could not be redistributed until their associated
projects were completed, sometimes five or more years later; as
a result, reallocations would be delayed for several years. Third,
the distribution of funding among NIH Institutes is determined by
Congress and incorporates input from NIH itself, scientists, health
care providers, and special interest groups. Thus, fiscal and
political constraints likely additionally tempered the NIH’s ability
to implement the IOM recommendations. Finally, without regard
to overall disease funding alignment, substantial financing ($1.8
billion, 6.3% 2006 NIH budget) was invested in the creation of
Table 3. Ranked Differences between Expected and Actual NIH Funding According to Year of Funding and United States Disease
Burden Measure(s) Used.
Millions of Dollars
(ascending rank*)
1996 2006
Univariate{
Standard
Univariate{
Standard Multivariable with
Public Interest Variables1
Constrained
Multivariable"
Condition or Disease
Depression 2178 (1) 2719 (1) 2689 (2) 2951 (2)
Perinatal Conditions 2124 (2) 297 (27) 114 (23) 2194 (11)
Stroke 2121 (3) 2278 (6) 2288 (5) 2170 (13)
Injuries 2113 (4) 2691 (2) 2123 (12) 2721 (3)
Chronic obstructive pulmonary disorder 2101(5) 2613 (3) 2357(3) 2554(5)
Pneumonia 252(6) 27 (21) 154 (27) 270 (27)
Peptic ulcer disease 246(7) 2105 (14) 275 (14) 218 (19)
Lung cancer 246(8) 2364 (5) 2328 (4) 21358 (1)
Schizophrenia 237(9) 244 (18) 129 (24) 94 (24)
Ischemic heart disease 230(10) 2490 (4) 2731 (1) 2721 (4)
Uterine cancer 229(11) 2146 (10) 294 (13) 2111 (15)
Asthma 225(12) 2198 (8) 2235 (6) 40 (21)
Otitis media 219(13) 297 (15) 270 (15) 227 (18)
Colorectal cancer 216(14) 2168 (9) 21 (19) 2519 (7)
Ovarian cancer 215(15) 2135 (11) 2196 (9) 2337 (9)
Epilepsy 210(16) 2133 (12) 2226 (7) 2101 (16)
Parkinson’s disease 23(17) 290 (17) 2183 (10) 2363 (8)
Cervical cancer 28(18) 2113 (13) 244 (17) 2223 (10)
Prostate cancer 32 (19) 56 (22) 23 (18) 68 (22)
Tuberculosis 44 (20) 89 (23) 96 (22) 97 (25)
Multiple sclerosis 52 (21) 295 (16) 2222 (8) 296 (17)
Sexually transmitted disease 58 (22) 110 (24) 153 (26) 198 (26)
Alcohol abuse 61 (23) 2202 (7) 152 (25) 2152 (14)
Cirrhosis 67 (24) 25 (20) 255 (16) 2178 (12)
Dental and oral disorders 130 (25) 113 (25) 74 (20) 90 (23)
Dementia 183 (26) 18 (19) 2159 (11) 2524 (6)
Diabetes mellitus 197(27) 390 (28) 160 (28) 382 (28)
Breast cancer 346 (28) 258 (26) 92 (21) 39 (20)
AIDS 1664 (29) 2474 (29) 2306 (29) 1835 (29)
*Ascending rank, from most underfunded disease condition (indicated by negative numbers) to most overfunded (positive numbers) as predicted by each model.
{ Univariate linear regression of the association between 2004 disease-specific Disability-Adjusted Life-Years (DALYs) and the outcome NIH dollars. Differences between
expected and actual funding levels in 1996 are adjusted for inflation to 2006 dollar equivalents, but are otherwise unchanged from those reported by Gross et al.
{ Standard univariate linear regression of the outcome NIH dollars as predicted by disease-specific DALYs. A stepwise forward multivariable model retained only DALYs
as a predictor.
1 Standard multivariable linear regression of the outcome NIH dollars as predicted by disease-specific DALYs and charity revenue.
" The constrained model is the multivariable linear regression model where the predicted NIH dollars are obligated to be proportional to disease-specific DALYs after
adjustment for total number of hospital discharges and average hospital charges.
doi:10.1371/journal.pone.0016837.t003
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Figure 2. NIH Funding in 2006 and US Disease Burden in DALYs in 2004 for 29 Common Medical Conditions. The solid line represents
the results of a traditional multivariable analysis, showing the relationship between US disease-specific DALYs burden and actual 2006 NIH funding
dollars. The dashed line projects NIH funding levels in a similar multivariable model that requires that a disease with no burden receives no funding
(constrained model). Though the models produce similar results, several diseases that would be considered overfunded in one model are considered
underfunded in the other. For example, cervical cancer appears to be overfunded relative to the dashed line, while it is underfunded relative to the
solid one.
doi:10.1371/journal.pone.0016837.g002
Figure 1. Ten-year Comparison of Differences Between Actual and Expected Disease-Specific NIH Funding Relative to US Burden of
Disease in DALYs. A comparison of differences between actual and expected funding values as predicted byDALYs burden alone in 1996 (light blue)
and 2006 (navy). Negative values reflect actual funding dollars less than expected and positive values represent actual funding dollars more than expected.
doi:10.1371/journal.pone.0016837.g001
NIH Funding Levels and Burden of Disease
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three new centers (National Institution for Biomedical Imaging
and Bioengineering, Center for Complementary and Alternative
Medicine, and National Center for Minority Health and Health
Disparities) [41], establishment of the cross-cutting Roadmap
Initiatives [42], and expanded emphasis on career training awards
[43].
The NIH has recently taken steps to integrate more effectively
the IOM priority-setting criteria. In 2007, the Division of Program
Coordination, Planning, and Strategic Initiatives (DPCPSI) was
established for the purposes of identifying scientific opportunities,
public health challenges, and scientific knowledge gaps, and to
improve portfolio analysis and priority-setting [44]. In 2009, a
more consistent and transparent system for the tracking of disease-
based funding was launched. Also, as part of the NIH’s $10.4
billion allocation in the American Recovery & Reinvestment Act,
$400 million will be dedicated to comparative effectiveness
research that specifically evaluates the effects of clinical manage-
ment on comprehensive public health outcomes such as mortality,
morbidity, and quality of life [45].
Our study has several limitations. First, the accounting of
disease funding in 2006 by NIH is not standardized nor is the
reliability known [32]. However, no alternative source of
information is publicly available and historical and new account-
ing methods yielded similarly poor correlations with burden.
Second, we did not evaluate other sources of federal, nonprofit,
and industry funding. Conditions well-funded by organizations
other than the NIH may justify a corresponding decrease in NIH
funding [46]. However, other sources of federal funding–The
Centers for Disease Control and Prevention, Agency for
Healthcare Research and Quality, and the Food and Drug
Administration–distributed only 3.3% of all Department of Health
and Human Services dollars dedicated to life sciences research in
2006. Similarly, the total life science research dollars spent by the
Department of Defense and Department of Veterans Affairs was
equivalent to less than 7% of the total amount disbursed by the
NIH [47,48]. Thus, the total dollars spent on complementary
projects by other federal institutions does not fully explain the poor
correlation between disease burden and NIH funding. Although
biomedical and pharmaceutical industry research funding in the
United States was 1.6 times the amount allocated by the NIH in
2006, fully 49% was dedicated to supporting clinical trials less
likely to have a widespread public health benefit [49]. Unfortu-
nately, funding by disease for these sectors is not available, except
for limited therapeutic areas [50], and no such figures exist for
private foundations. Third, global estimates of disease burden
from the WHO GBD are uncertain due to incompleteness and
bias, particularly in low-income countries [51]. However, these
estimates are the best available and are particularly accurate for
Figure 3. Differences Between Actual and Expected Disease-Specific Funding in 2006. Determinations of actual funding relative to
expected funding were generally similar among separate analytic models predicting funding levels from disease burden measures. Univariate results
are based on DALYs alone (navy), the only variable retained in a stepwise forward multivariable model. A traditional multivariable model including
public interest variables (grey-blue) retained only DALYs and total charity revenue in the model. A constrained multivariable (light blue)
model required an intercept of zero-zero to impose a requirement that conditions with no burden received no funding and retained DALYs, total
number of US hospital discharges, and mean charge per hospitalization in 2004.
doi:10.1371/journal.pone.0016837.g003
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the US. Fourth, to permit comparisons to the prior study and to
make the study feasible, many diseases and conditions funded by
the NIH were omitted from our analysis. Still, an assessment of the
responsive of NIH to prior recommendation was central to our
study and power would not be expected to dramatically impact
our findings. Fifth, the prior analysis utilized estimates for world
market economies [5], while we used North American numbers.
The data we used better approximates US burdens, strengthening
our conclusions, but could affect the assessment of interval change.
Since we found a poorer correlation with funding than previous
estimates, this did not impact our conclusions. Finally, none of the
measures of disease burden individually or collectively fully
captures the health and economic cost of these conditions. A
better metric might capture the true societal cost of disease
through a comprehensive assessment of total healthcare costs and
a valuation of both deaths and DALYs [52].
Overall, funding levels today are less well aligned with DALYs
compared to 10 years ago, suggesting that the IOM’s 1998
priority-setting recommendations have not been implemented
effectively. Accounting for other measures of disease burden did
not substantially improve alignment. As a recipient of substantial
governmental support, clear articulation of the rationale for NIH
spending may be expected by Congress and the public, and a lack
of clear alignment with measures of public burden could
encourage special interests to further erode the scientific
independence of NIH or to raise questions about its management.
The use of more consistent accounting methods for disease
funding, more comprehensive measures of burden and future risk
that include impact on health and expenditures, and the timely
dissemination of benchmarks on the alignment of disease burden
to funding could help to make NIH funding priorities more
rationale and transparent.
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